DONNA

TapImmune Doses First Patient in its Phase 2 Triple Negative Trial

June 22nd, 2016 | Posted In: Donna Blog, Front Page Feature, Research Updates

DONNA partner TapImmune announced a major milestone of dosing its first patient in a Phase 2 trial for triple negative breast cancer with its cancer vaccine TPIV 200. The randomized, open label Phase 2 study is expected to enroll a total of 80 subjects. The primary endpoints are dosing regimens and safety. Secondary endpoints are T-cell specific responses and evaluation of objective responses.  TPIV 200 is currently being investigated in another Phase 2 trial at the Mayo Clinic that is expected to start enrollment later this year.  GO TEAM GO!

 

Leave a Reply

Be the First to Comment!

Notify of
wpDiscuz

Stay Posted

Stay Posted

Locals Rule

Locals Rule

YesWay

YesWay

Team Donna

Team Donna

Donna partners

The Donna Foundation

The Donna Foundation

Jeff Galloway

Jeff Galloway

Mayo Clinic

Mayo Clinic

Learn More

First Coast News